

Mary Frances McMullin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764989/publications.pdf>

Version: 2024-02-01

235
papers

11,751
citations

41627

51
h-index

35168

102
g-index

237
all docs

237
docs citations

237
times ranked

10764
citing authors

#	ARTICLE	IF	CITATIONS
1	CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients. <i>Irish Journal of Medical Science</i> , 2023, 192, 591-593.	0.8	1
2	A randomized phase 3 trial of interferon- β vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	0.6	45
3	FEDORA: The Beginning of a Beautiful Friendship?. , 2022, 19, .		0
4	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. <i>Leukemia</i> , 2021, 35, 1197-1202.	3.3	9
5	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. <i>Leukemia</i> , 2021, 35, 2424-2430.	3.3	8
6	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. <i>Blood Cancer Journal</i> , 2021, 11, 53.	2.8	24
7	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021, 39, 890-901.	0.8	20
8	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	1.1	31
9	Protein tyrosine phosphatase receptor type C (PTPRC or CD45). <i>Journal of Clinical Pathology</i> , 2021, 74, 548-552.	1.0	90
10	Molecular pathogenesis of the myeloproliferative neoplasms. <i>Journal of Hematology and Oncology</i> , 2021, 14, 103.	6.9	49
11	Genetic Background of Congenital Erythrocytosis. <i>Genes</i> , 2021, 12, 1151.	1.0	8
12	Hereditary thrombocytosis: the genetic landscape. <i>British Journal of Haematology</i> , 2021, 194, 1098-1105.	1.2	6
13	Significance of NPM1 Gene Mutations in AML. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10040.	1.8	18
14	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021, 192, 62-74.	1.2	18
15	Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera. <i>Blood</i> , 2021, 138, 3644-3644.	0.6	0
16	A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. <i>Blood</i> , 2021, 138, 2355-2355.	0.6	0
17	Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study. <i>Blood</i> , 2021, 138, 1507-1507.	0.6	0
18	A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms. <i>Irish Journal of Medical Science</i> , 2020, 189, 621-626.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
20	Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2669.	1.7	6
21	Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. <i>Journal of Clinical Pathology</i> , 2020, 74, jclinpath-2020-206570.	1.0	10
22	Aetiology of Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1810.	1.7	16
23	Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2020, 4, e327.	1.2	18
24	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. <i>Leukemia</i> , 2020, 34, 2234-2237.	3.3	34
25	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
26	Ruxolitinib: gaining more than intended. <i>Blood</i> , 2020, 135, 983-984.	0.6	0
27	Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study. <i>Blood</i> , 2020, 136, 33-35.	0.6	6
28	Presidential address to the Ulster Medical Society on 3rd October 2019. <i>Ulster Medical Journal</i> , 2020, 89, 72-76.	0.2	0
29	Somatic <i>SF3B1</i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. <i>Journal of Clinical Pathology</i> , 2019, 72, 778-782.	1.0	17
30	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. <i>Experimental Hematology</i> , 2019, 79, 26-34.	0.2	8
31	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
32	Facing erythrocytosis: Results of an international physician survey. <i>American Journal of Hematology</i> , 2019, 94, E225-E227.	2.0	10
33	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. <i>Blood</i> , 2019, 134, 2107-2111.	0.6	12
34	Reducing the burden of MPN. <i>Blood</i> , 2019, 134, 1483-1484.	0.6	0
35	Acute promyelocytic leukaemia (<i>APML</i>) with cryptic <i>PML-RARA</i> fusion has a clinical course comparable to classical <i>APML</i> with t(15;17)(q24.1;q21.2) translocation. <i>British Journal of Haematology</i> , 2019, 186, 155-157.	1.2	3
36	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. <i>British Journal of Haematology</i> , 2019, 184, 161-175.	1.2	76

#	ARTICLE	IF	CITATIONS
37	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2019, 184, 176-191.	1.2	102
38	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. <i>Blood</i> , 2019, 134, 2943-2943.	0.6	4
39	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
40	Diagnostic workflow for hereditary erythrocytosis and thrombocytosis. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 391-396.	0.9	12
41	<i>JAK2</i> mutations in idiopathic erythrocytosis. <i>British Journal of Haematology</i> , 2018, 181, 270-272.	1.2	13
42	The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. <i>Annals of Human Genetics</i> , 2018, 82, 114-118.	0.3	6
43	A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective. <i>Expert Review of Hematology</i> , 2018, 11, 25-35.	1.0	0
44	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. <i>Journal of Clinical Oncology</i> , 2018, 36, 3361-3369.	0.8	54
45	The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. <i>Journal of Translational Medicine</i> , 2018, 16, 360.	1.8	50
46	Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series. <i>Thrombosis Journal</i> , 2018, 16, 33.	0.9	11
47	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018, 379, 1416-1430.	13.9	442
48	Absence of <i>JAK2</i> and <i>CALR</i> Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels. <i>Acta Haematologica</i> , 2018, 139, 217-219.	0.7	3
49	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018, 132, 3032-3032.	0.6	6
50	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	0.6	39
51	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
52	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. <i>Blood</i> , 2018, 132, 3037-3037.	0.6	0
53	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. <i>Blood</i> , 2018, 132, 1784-1784.	0.6	0
54	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. <i>Blood</i> , 2018, 132, 1762-1762.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. <i>Blood</i> , 2018, 132, 1759-1759.	0.6	0
56	Equivalence of BCSH and WHO diagnostic criteria for ET. <i>Leukemia</i> , 2017, 31, 527-528.	3.3	6
57	70 years of the <i>JCP</i>-highly cited papers: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. <i>Journal of Clinical Pathology</i> , 2017, 70, 909-910.	1.0	1
58	Epigenetics in Myeloproliferative Neoplasms. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1660-1667.	1.6	29
59	Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. <i>Clinical Cancer Research</i> , 2017, 23, 6430-6440.	3.2	74
60	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. <i>Blood</i> , 2017, 130, 1889-1897.	0.6	130
61	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. <i>Leukemia</i> , 2017, 31, 882-888.	3.3	40
62	Management of polycythaemia vera: a critical review of current data. <i>British Journal of Haematology</i> , 2016, 172, 337-349.	1.2	28
63	LNK mutations and myeloproliferative disorders. <i>American Journal of Hematology</i> , 2016, 91, 248-251.	2.0	31
64	The Calreticulin gene and myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2016, 69, 841-845.	1.0	12
65	Coexistence of inversion 16 in chronic myeloid leukaemia in blast crisis. <i>Journal of Hematopathology</i> , 2016, 9, 155-160.	0.2	0
66	Congenital erythrocytosis. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 59-65.	0.7	13
67	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	1.7	118
68	Investigation and Management of Erythrocytosis. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 342-347.	1.2	36
69	Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. <i>Haematologica</i> , 2016, 101, 1306-1318.	1.7	66
70	Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International Context. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, e1626-e1631.	2.3	0
71	Minor allele frequency of myeloproliferative neoplasm mutations in the Irish blood donor population. <i>Hematological Oncology</i> , 2016, 34, 161-164.	0.8	0
72	The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 102-106.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. <i>Blood</i> , 2016, 128, 1065-1065.	0.6	3
74	A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results. <i>Blood</i> , 2016, 128, 4261-4261.	0.6	6
75	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016, 128, 4271-4271.	0.6	5
76	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	0.6	32
77	Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 1929-1929.	0.6	0
78	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. <i>Blood</i> , 2016, 128, 5479-5479.	0.6	0
79	(32)P in the treatment of myeloproliferative disorders. <i>Ulster Medical Journal</i> , 2016, 85, 83-5.	0.2	2
80	Outcomes of pregnancy in patients with congenital erythrocytosis. <i>British Journal of Haematology</i> , 2015, 170, 586-588.	1.2	3
81	Molecular diagnostics of myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2015, 95, 270-279.	1.1	67
82	Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. <i>Experimental Hematology and Oncology</i> , 2015, 5, 14.	2.0	3
83	A Japanese Family with Congenital Erythrocytosis Caused by Haemoglobin Bethesda. <i>Internal Medicine</i> , 2015, 54, 2389-2393.	0.3	0
84	The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. <i>Experimental Hematology and Oncology</i> , 2015, 4, 26.	2.0	36
85	Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls. <i>American Journal of Hematology</i> , 2015, 90, 864-870.	2.0	33
86	Management of newly diagnosed chronic myeloid leukaemia during a twin pregnancy using leucapheresis: Case report and review of the literature. <i>Transfusion and Apheresis Science</i> , 2015, 52, 199-203.	0.5	5
87	Protein deregulation associated with breast cancer metastasis. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 415-423.	3.2	7
88	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015, 47, 717-726.	9.4	310
89	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1295-1305.	5.1	433
90	Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2015, 126, 5179-5179.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls Using Multivariate Analysis. <i>Blood</i> , 2015, 126, 1620-1620.	0.6	0
92	Myeloproliferative Neoplasms: An in-Depth Case-Control (MOSAICC) Study. <i>Blood</i> , 2015, 126, 1621-1621.	0.6	12
93	Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance. <i>Blood</i> , 2015, 126, 3630-3630.	0.6	0
94	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial. <i>Blood</i> , 2015, 126, 221-221.	0.6	1
95	The role of PHD2 mutations in the pathogenesis of erythrocytosis. <i>Hypoxia (Auckland, N Z)</i> , 2014, 2, 71.	1.9	39
96	Clinical utility gene card for: Hereditary thrombocythemia. <i>European Journal of Human Genetics</i> , 2014, 22, 293-293.	1.4	8
97	Epidemiology of MPN: What Do We Know?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 340-349.	1.2	27
98	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. <i>Human Mutation</i> , 2014, 35, 15-26.	1.1	101
99	Assessment of <i>CALR</i> mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 800-802.	1.2	30
100	Use of <i>JAK</i> inhibitors in the management of myelofibrosis: a revision of the <i>British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012</i> . <i>British Journal of Haematology</i> , 2014, 167, 418-420.	1.2	37
101	Secondary erythrocytosis. <i>Hematology</i> , 2014, 19, 183-184.	0.7	10
102	Update in the myeloproliferative neoplasms. <i>Clinical Medicine</i> , 2014, 14, s66-s70.	0.8	0
103	Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 42-48.	1.3	65
104	How common are myeloproliferative neoplasms? A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2014, 89, 581-587.	2.0	141
105	Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras. <i>British Journal of Haematology</i> , 2014, 165, 519-528.	1.2	13
106	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. <i>Leukemia Research</i> , 2014, 38, 310-315.	0.4	12
107	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. <i>British Journal of Haematology</i> , 2014, 167, 421-423.	1.2	40
108	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. <i>Leukemia Research</i> , 2014, 38, 816-821.	0.4	12

#	ARTICLE	IF	CITATIONS
109	Community-acquired infections and their association with myeloid malignancies. <i>Cancer Epidemiology</i> , 2014, 38, 56-61.	0.8	36
110	Mutational spectrum defines primary and secondary myelofibrosis. <i>Haematologica</i> , 2014, 99, 2-3.	1.7	10
111	Erythrocytosis associated with a novel missense mutation in the BPGM gene. <i>Haematologica</i> , 2014, 99, e201-e204.	1.7	35
112	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m ² and 6mg/m ² Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. <i>Blood</i> , 2014, 124, 2308-2308.	0.6	2
113	A phase II study of vorinostat (<sc>MK</sc>â€0683) in patients with polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2013, 162, 498-508.	1.2	65
114	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. <i>Leukemia</i> , 2013, 27, 2032-2039.	3.3	96
115	Molecular diagnosis of the myeloproliferative neoplasms: <sc>UK</sc> guidelines for the detection of <i><sc>JAK</sc>2</i> </i><sc>V</sc>617<sc>F</sc> and other relevant mutations. <i>British Journal of Haematology</i> , 2013, 160, 25-34.	1.2	87
116	Prognostic and therapeutic relevance of câ€<sc>FLIP</sc> in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 188-198.	1.2	39
117	Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. <i>Leukemia</i> , 2013, 27, 843-851.	3.3	74
118	The diagnosis and management of erythrocytosis. <i>BMJ</i> , The, 2013, 347, f6667-f6667.	3.0	67
119	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. <i>Blood</i> , 2013, 122, 1384-1394.	0.6	123
120	Diagnostic pathway for the investigation of thrombocytosis. <i>British Journal of Haematology</i> , 2013, 161, 604-606.	1.2	6
121	Characteristics and outcomes ofâ€%haematology patients admitted toâ€%the intensive care unit. <i>Nursing in Critical Care</i> , 2013, 18, 193-199.	1.1	6
122	The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. <i>Leukemia</i> , 2013, 27, 75-81.	3.3	146
123	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. <i>Blood</i> , 2013, 121, 4778-4781.	0.6	219
124	Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1734-1738.	0.8	26
125	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. <i>Haematologica</i> , 2013, 98, 1216-1225.	1.7	39
126	Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. <i>Journal of Clinical Investigation</i> , 2013, 123, 2169-2182.	3.9	36

#	ARTICLE	IF	CITATIONS
127	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. <i>Blood</i> , 2013, 122, 358-358.	0.6	9
128	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013, 122, 394-394.	0.6	29
129	Polycythemia-Inducing Mutations In The Erythropoietin Receptor (EPOR): Mechanism and Function Elucidated By EGFR α -EPOR Chimeras. <i>Blood</i> , 2013, 122, 2174-2174.	0.6	0
130	Diagnosis and management of congenital and idiopathic erythrocytosis. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 391-398.	1.1	24
131	Clinical utility gene card for: familial erythrocytosis. <i>European Journal of Human Genetics</i> , 2012, 20, 4-4.	1.4	10
132	Commentary. <i>Clinical Chemistry</i> , 2012, 58, 335-335.	1.5	1
133	Management of myelofibrosis: a survey of current practice in the United Kingdom. <i>Journal of Clinical Pathology</i> , 2012, 65, 1124-1127.	1.0	2
134	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. <i>Blood</i> , 2012, 120, 2704-2707.	0.6	94
135	JAK2 inhibitor and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. <i>British Journal of Haematology</i> , 2012, 157, 426-437.	1.2	19
136	Guideline for the diagnosis and management of myelofibrosis. <i>British Journal of Haematology</i> , 2012, 158, 453-471.	1.2	89
137	Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2012, 87, 175-182.	2.0	35
138	Two new mutations in the <i>HIF2A</i> gene associated with erythrocytosis. <i>American Journal of Hematology</i> , 2012, 87, 439-442.	2.0	37
139	Symptom Burden Among PV and ET Patients Receiving A Novel Histone Deacetylase Inhibitor: Findings From a Open-Label Phase II Study. <i>Blood</i> , 2012, 120, 1736-1736.	0.6	1
140	Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 $\times 10^9/L$ and 99 $\times 10^9/L$. <i>Blood</i> , 2012, 120, 177-177.	0.6	7
141	The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. <i>Blood</i> , 2012, 120, 2838-2838.	0.6	7
142	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2012, 120, 803-803.	0.6	4
143	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. <i>Blood</i> , 2012, 120, 889-889.	0.6	4
144	Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification. , 2012, , 37-45.		0

#	ARTICLE	IF	CITATIONS
145	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. <i>Blood</i> , 2011, 117, 2813-2816.	0.6	190
146	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
147	A nonsynonymous <i>LNK</i> polymorphism associated with idiopathic erythrocytosis. <i>American Journal of Hematology</i> , 2011, 86, 962-964.	2.0	30
148	Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-1α gain-of-function mutation. <i>FASEB Journal</i> , 2011, 25, 2001-2011.	0.2	86
149	A Novel Base Change Leading to Hb Vanderbilt [²⁸⁹ (F5)Ser [→] Arg, AG<i>T</i>>AG<i>A</i>]. <i>Hemoglobin</i> , 2011, 35, 428-429.	0.4	1
150	Increased MSI2 expression Is Associated with Aggressive CML and AML. <i>Blood</i> , 2011, 118, 2516-2516.	0.6	0
151	First Achievements of MPN&MPNr-EuroNet (COST Action BM0902), a New European Network Dedicated to the Diagnosis of Myeloproliferative Neoplasms and Hereditary Erythrocytosis and Thrombocytosis. <i>Blood</i> , 2011, 118, 2809-2809.	0.6	6
152	Two routes to leukemic transformation after a JAK2 mutation in a positive myeloproliferative neoplasm. <i>Blood</i> , 2010, 115, 2891-2900.	0.6	269
153	The finding of a reciprocal whole-arm translocation t(X;12)(p10;p10) in association with atypical chronic myeloid leukaemia. <i>Medical Oncology</i> , 2010, 27, 760-762.	1.2	2
154	British Society of Haematology, Slide Session presented at the Annual Scientific Meeting, Brighton 2009. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 616-624.	0.7	0
155	Tumour Lysis Syndrome after Splenic Irradiation in a Patient with JAK2 V617F Post-polycythaemia Vera Myelofibrosis. <i>Clinical Oncology</i> , 2010, 22, 893.	0.6	4
156	Guideline for investigation and management of adults and children presenting with a thrombocytosis. <i>British Journal of Haematology</i> , 2010, 149, 352-375.	1.2	253
157	Regulation of human metabolism by hypoxia-inducible factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12722-12727.	3.3	160
158	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 4517-4523.	0.6	93
159	HIF pathway mutations and erythrocytosis. <i>Expert Review of Hematology</i> , 2010, 3, 93-101.	1.0	26
160	The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 "Pick a Winner" Comparison. <i>Blood</i> , 2010, 116, 18-18.	0.6	11
161	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. <i>Blood</i> , 2010, 116, 3427-3427.	0.6	6
162	SOCS3 Phosphorylation In Myeloproliferative Neoplasms. <i>Blood</i> , 2010, 116, 3083-3083.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. <i>Haematologica</i> , 2009, 94, 296-298.	1.7	6
164	SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. <i>Haematologica</i> , 2009, 94, 576-580.	1.7	25
165	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. <i>Blood</i> , 2009, 113, 4829-4833.	0.6	229
166	Idiopathic erythrocytosis: a disappearing entity. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 629-635.	0.9	46
167	Erythrocytosis-associated HIF-2 β Mutations Demonstrate a Critical Role for Residues C-terminal to the Hydroxylacceptor Proline. <i>Journal of Biological Chemistry</i> , 2009, 284, 9050-9058.	1.6	55
168	Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. <i>Heart</i> , 2009, 95, 1225-1229.	1.2	31
169	Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1721-1722.	0.6	9
170	Proteasome proteolytic profile is linked to Bcr-Abl expression. <i>Experimental Hematology</i> , 2009, 37, 357-366.	0.2	16
171	Clinical and hematological presentation of children and adolescents with polycythemia vera. <i>Annals of Hematology</i> , 2009, 88, 713-719.	0.8	39
172	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. <i>British Journal of Haematology</i> , 2009, 144, 904-908.	1.2	75
173	Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosis. <i>Haematologica</i> , 2009, 94, 1321-1322.	1.7	43
174	Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study.. <i>Blood</i> , 2009, 114, 3904-3904.	0.6	3
175	Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 "Pick a Winner" Comparison.. <i>Blood</i> , 2009, 114, 486-486.	0.6	1
176	The therapeutic potential of the proteasome in leukaemia. <i>Hematological Oncology</i> , 2008, 26, 73-81.	0.8	15
177	Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukaemia in patients from Northern Ireland. <i>Leukemia</i> , 2008, 22, 1629-1631.	3.3	13
178	Reply to Ostrovosky et al.. <i>Leukemia</i> , 2008, 22, 1632-1632.	3.3	1
179	The classification and diagnosis of erythrocytosis. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 447-459.	0.7	92
180	Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. <i>British Journal of Haematology</i> , 2008, 142, 622-626.	1.2	33

#	ARTICLE	IF	CITATIONS
181	Câ€CSF increases proteasome activity in myeloid cells. British Journal of Haematology, 2008, 143, 598-601.	1.2	1
182	Mutation of the von Hippel-Lindau Gene Alters Human Cardiopulmonary Physiology. Advances in Experimental Medicine and Biology, 2008, 605, 51-56.	0.8	15
183	Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. Hematology, 2008, 13, 133-136.	0.7	7
184	Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia. Journal of Clinical Pathology, 2008, 61, 903-908.	1.0	9
185	A Gain-of-Function Mutation in the <i>HIF2A</i> Gene in Familial Erythrocytosis. New England Journal of Medicine, 2008, 358, 162-168.	13.9	287
186	Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood, 2008, 111, 5400-5402.	0.6	113
187	Low-dose thalidomide in myelofibrosis. Haematologica, 2008, 93, 1100-1101.	1.7	35
188	HIF-2alpha Associated Familial Erythrocytosis Supports the PHD2-HIF- 2alpha-VHL Axis as the Major Regulator of Erythropoietin Production. Blood, 2008, 112, 481-481.	0.6	2
189	The myeloproliferative disorderâ€™associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 2007, 109, 4924-4929.	0.6	112
190	Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2Î± iron-responsive element?. Blood, 2007, 110, 2776-2777.	0.6	5
191	A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood, 2007, 110, 2193-2196.	0.6	140
192	Comparison of diagnostic criteria for polycythaemia vera. Hematology, 2007, 12, 123-130.	0.7	9
193	Pyruvate kinase deficient hemolytic anemia in the Northern Irish population. Blood Cells, Molecules, and Diseases, 2007, 39, 189-194.	0.6	8
194	JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. New England Journal of Medicine, 2007, 356, 459-468.	13.9	1,173
195	Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 363-377.	1.5	15
196	The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica, 2007, 92, 1607-1614.	1.7	84
197	A review of the therapeutic agents used in the management of polycythaemia vera. Hematological Oncology, 2007, 25, 58-65.	0.8	9
198	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 2007, 109, 1114-1124.	2.0	559

#	ARTICLE	IF	CITATIONS
199	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 2007, 138, 821-822.	1.2	99
200	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. , 2007, 109, 1114.		1
201	Erythrocytosis Caused by Mutations in the PHD2 and VHL Genes.. Blood, 2007, 110, 3663-3663.	0.6	1
202	Analysis of HOXA5 and HOXB3 Expression Complements Conventional Cytogenetic Analysis in Acute Myeloid Leukemia.. Blood, 2007, 110, 2388-2388.	0.6	1
203	Genotyping of thiopurine methyltransferase in patients with acute leukemia using LightCycler PCR. Leukemia and Lymphoma, 2006, 47, 1624-1628.	0.6	8
204	Mutation of von Hippelâ€“Lindau Tumour Suppressor and Human Cardiopulmonary Physiology. PLoS Medicine, 2006, 3, e290.	3.9	163
205	Oxygen Sensing: Recent Insights from Idiopathic Erythrocytosis. Cell Cycle, 2006, 5, 941-945.	1.3	15
206	Anthracycline cardiotoxicityThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 1137-1138.	1.0	22
207	A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 654-659.	3.3	292
208	Artificial Neural Network Analysis of HOX Gene Expression Profiles Predicts Prognostic Subgroups in Acute Myeloid Leukemia.. Blood, 2006, 108, 2318-2318.	0.6	0
209	HOXA6: A Novel Candidate Gene in AML.. Blood, 2006, 108, 2312-2312.	0.6	0
210	JAK2 V617F: a single mutation in the myeloproliferative group of disorders. Ulster Medical Journal, 2006, 75, 112-9.	0.2	19
211	The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica, 2006, 91, 413-4.	1.7	18
212	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 2005, 130, 174-195.	1.2	314
213	Acute intestinal obstruction due to intramural haemorrhage in small intestine in a patient with severe haemophilia A and inhibitor. European Journal of Haematology, 2005, 75, 164-166.	1.1	15
214	The V617F JAK2 mutation and the myeloproliferative disorders. Hematological Oncology, 2005, 23, 91-93.	0.8	33
215	Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.. Blood, 2005, 106, 543-543.	0.6	6
216	The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood, 2004, 103, 1937-1940.	0.6	67

#	ARTICLE	IF	CITATIONS
217	Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.. <i>Blood</i> , 2004, 104, 872-872.	0.6	17
218	Haemoglobin during pregnancy: relationship to erythropoietin and haematinic status. <i>European Journal of Haematology</i> , 2003, 71, 44-50.	1.1	40
219	The Optimal Management of Polycythaemia Vera. <i>British Journal of Haematology</i> , 2003, 120, 543-544.	1.2	7
220	A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. <i>Molecular Cancer</i> , 2003, 2, 31.	7.9	52
221	Chromosomal abnormalities in Ph- cells of patients on imatinib. <i>Blood</i> , 2003, 102, 2700-2701.	0.6	22
222	Global down-regulation of HOX gene expression in PML-RAR α acute promyelocytic leukemia identified by small-array real-time PCR. <i>Blood</i> , 2003, 101, 1558-1565.	0.6	56
223	Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. <i>Blood</i> , 2003, 102, 1097-1099.	0.6	91
224	Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. <i>Blood</i> , 2002, 100, 3447-3449.	0.6	40
225	Hepatosplenic Candidiasis, its Treatment and Effect on Remission Status in Patients with Acute Leukaemia—a Report of Five Cases. <i>Hematology</i> , 2001, 6, 331-335.	0.7	1
226	Survival from Acute Myeloid Leukaemia in Patients Over 55 Years of Age in Northern Ireland: A Discrete Population. <i>Hematology</i> , 2001, 6, 103-110.	0.7	4
227	Homocysteine and methylmalonic acid as indicators of folate and vitamin B12 deficiency in pregnancy. <i>International Journal of Laboratory Hematology</i> , 2001, 23, 161-165.	0.2	37
228	The molecular basis of disorders of red cell enzymes. <i>Journal of Clinical Pathology</i> , 1999, 52, 241-244.	1.0	33
229	The molecular basis of disorders of the red cell membrane. <i>Journal of Clinical Pathology</i> , 1999, 52, 245-248.	1.0	23
230	Erythropoietin receptor and hematological disease. , 1999, 60, 55-60.		8
231	Erythrocytosis due to a mutation in the erythropoietin receptor gene. <i>British Journal of Haematology</i> , 1998, 100, 407-410.	1.2	46
232	Sequence Analysis of the 3 α Hypoxia-Responsive Element of the Human Erythropoietin Gene in Patients with Erythrocytosis. <i>Biochemical and Molecular Medicine</i> , 1997, 62, 132-134.	1.5	14
233	Prevention of Infection after Splenectomy. <i>BioDrugs</i> , 1995, 3, 191-195.	0.7	0
234	Comparison of the mouse spleen cell assay and a radioimmunoassay for the measurement of serum erythropoietin. <i>British Journal of Haematology</i> , 1988, 70, 117-120.	1.2	34

#	ARTICLE	IF	CITATIONS
235	Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis. , 0, , 1-8.		0